Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA - TheNote.app

GSK press releases

Follow

Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA

Breakthrough Therapy Designation added to Fast Track Designation, recognising potential for substantial improvement over existing treatments

https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-priority-review-and-granted-breakthrough-therapy-designation-by-the-us-fda/ gsk.com

RSS Hunter • Apr 28